Ligand Pharmaceuticals
LGND
357 hedge funds and large institutions have $4.15B invested in Ligand Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 133 increasing their positions, 115 reducing their positions, and 43 closing their positions.
37% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 43
22% more call options, than puts
Call options by funds: $8.48M | Put options by funds: $6.95M
16% more repeat investments, than reductions
Existing positions increased: 133 | Existing positions reduced: 115
7% more capital invested
Capital invested by funds: $3.89B → $4.15B (+$264M)
2% more funds holding
Funds holding: 349 → 357 (+8)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
0.18% less ownership
Funds ownership: 104.47% → 104.29% (-0.18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$60.8M |
| 2 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
+$19M |
| 3 |
Bessemer Group
Woodbridge,
New Jersey
|
+$16.7M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$15.2M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$12.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$29.8M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$21M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$18.9M |
| 4 |
NAMI
Nomura Asset Management International
Philadelphia,
Pennsylvania
|
-$14M |
| 5 |
Goldman Sachs
New York
|
-$9.48M |
LGND Hedge Fund Activity: Q1 2026 in Review
357 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2026, worth a combined $4.15B — up 6.8% from $3.89B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new LGND positions and 43 closed out — a net gain of 16 holders — while 133 added to existing stakes and 115 trimmed.
The largest buyer was Invesco, adding an estimated $60.8M. The largest seller was UBS AM, cutting an estimated $29.8M.
- 357 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2026, up from 349 in Q4 2025.
- Funds reported $4.15B of Ligand Pharmaceuticals stock for Q1 2026, up 6.8% quarter-over-quarter.
- 59 funds opened new Ligand Pharmaceuticals positions in Q1 2026 and 43 closed out, a net change of +16 holders.
- The largest Ligand Pharmaceuticals buyer in Q1 2026 was Invesco, an estimated $60.8M added.
- The largest Ligand Pharmaceuticals seller in Q1 2026 was UBS AM, an estimated $29.8M sold.
Based on aggregated 13F filings for Q1 2026.